Zhixun Finance App learned that Bocom International released a research report, reaffirming Akeso's buy rating with a target price of HKD 70, which is one of the industry's first recommended symbols. The bank believes that this is still an excellent opportunity for the company's layout.

The report pointed out that the company's global first head-to-head Keytruda monotherapy Phase III clinical trial achieved excellent results in progression-free survival (PFS). The clinical results of HARMONi-2 are in line with expectations and are a revalidation of AK112 clinical treatment and global market potential. We will continue to pay attention to the disclosure of detailed data on PFS in September and the subsequent OS data updates. Although the existing PFS data is limited, we remain cautiously optimistic about the OS results.